Literature DB >> 3038661

Portal venous hemodynamics in hepatocellular carcinoma. Effects of hepatic artery embolization.

K Ohnishi, S Sato, T Tsunoda, S Sugita, F Nomura, S Iida.   

Abstract

Portal hemodynamics were studied in 55 patients with hepatocellular carcinoma in comparison with 41 normal subjects, using the duplex system that consists of an electronic sector scanner and a pulsed Doppler velocitometer. Changes of portal hemodynamics after transcatheter hepatic artery embolization were also investigated in 15 of the patients with hepatocellular carcinoma. The duplex system showed that 9 of the 55 had no Doppler signal in the portal trunk, suggesting portal vein thrombosis, 2 had hepatofugal flow in the portal trunk indicative of arterioportal shunts, and 44 had hepatopetal flow in the portal trunk. One of the 9 patients with no significant portal venous flow showed hepatopetal flow in collateral veins at the porta hepatis, suggesting cavernous transformation of the portal vein. All of these ultrasound findings were confirmed by subsequent celiac-mesenteric angiography. In 44 of the 55 patients there was no tumor invasion in the portal trunk, and portal venous flow was found to be close to that of normal subjects regardless of the stage or size of tumor, and tumor invasion into relatively large portal branches. After transcatheter hepatic artery embolization, portal venous flow was increased, even on the next day, and it remained increased for at least 2 wk. Thus, the duplex system is useful to study qualitative and quantitative changes of portal hemodynamics in hepatocellular carcinoma. Our observations suggest that the portal venous flow is kept relatively constant by some homeostatic mechanism even in advanced hepatocellular carcinoma until the tumor invades into the portal trunk, and that it increases when hepatic arterial flow is occluded.

Entities:  

Mesh:

Year:  1987        PMID: 3038661     DOI: 10.1016/0016-5085(87)90923-1

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  6 in total

1.  Hepatic perfusion changes after transcatheter arterial embolization (TAE) of hepatocellular carcinoma: measurement by dynamic computed tomography (CT).

Authors:  Y Tsushima; Y Unno; J Koizumi; S Kusano
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

2.  Foxp3+ regulatory T cells and the formation of portal vein tumour thrombus in patients with hepatocellular carcinoma.

Authors:  Shun Li Shen; Li Jian Liang; Bao Gang Peng; Qiang He; Ming Kuang; Jia Ming Lai
Journal:  Can J Surg       Date:  2011-04       Impact factor: 2.089

3.  Antipyrine clearance per unit liver volume in cirrhotics with and without hepatocellular carcinoma indicating a correlation with histological change of the liver.

Authors:  S Noda; S Kawata; S Miyoshi; Y Minami; S Tarui
Journal:  Gastroenterol Jpn       Date:  1989-04

Review 4.  Tumor in vein (LR-TIV) and liver imaging reporting and data system (LI-RADS) v2018: diagnostic features, pitfalls, prognostic and management implications.

Authors:  Roberta Catania; Kalina Chupetlovska; Amir A Borhani; Ekta Maheshwari; Alessandro Furlan
Journal:  Abdom Radiol (NY)       Date:  2021-09-14

5.  Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma.

Authors:  Bernhard Scheiner; Gregor Ulbrich; Mattias Mandorfer; Thomas Reiberger; Christian Müller; Fredrik Waneck; Michael Trauner; Claus Kölblinger; Arnulf Ferlitsch; Wolfgang Sieghart; Markus Peck-Radosavljevic; Matthias Pinter
Journal:  United European Gastroenterol J       Date:  2019-03-21       Impact factor: 4.623

6.  Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure.

Authors:  Constantine Frangakis; Jae Ho Sohn; Ahmet Bas; Julius Chapiro; Ruediger E Schernthaner; MingDe Lin; James P Hamilton; Timothy M Pawlik; Kelvin Hong; Rafael Duran
Journal:  Front Oncol       Date:  2021-11-05       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.